NYSE:AORT Artivion (AORT) Stock Price, News & Analysis → Your Money is Not Safe (From American Alternative) (Ad) Free AORT Stock Alerts $20.78 +0.46 (+2.26%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$20.36▼$20.8550-Day Range$17.55▼$21.6452-Week Range$12.16▼$21.90Volume133,013 shsAverage Volume219,787 shsMarket Capitalization$856.14 millionP/E RatioN/ADividend YieldN/APrice Target$23.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Artivion alerts: Email Address Artivion MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside13.1% Upside$23.50 Price TargetShort InterestBearish7.25% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.76Based on 2 Articles This WeekInsider TradingSelling Shares$2.89 M Sold Last QuarterProj. Earnings Growth123.08%From $0.26 to $0.58 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.47 out of 5 starsMedical Sector674th out of 909 stocksSurgical & Medical Instruments Industry73rd out of 94 stocks 2.5 Analyst's Opinion Consensus RatingArtivion has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArtivion has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted7.25% of the float of Artivion has been sold short.Short Interest Ratio / Days to CoverArtivion has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.Change versus previous monthShort interest in Artivion has recently increased by 3.27%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldArtivion does not currently pay a dividend.Dividend GrowthArtivion does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AORT. Previous Next 2.6 News and Social Media Coverage News SentimentArtivion has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Artivion this week, compared to 1 article on an average week.MarketBeat FollowsOnly 4 people have added Artivion to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Artivion insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,891,627.00 in company stock.Percentage Held by InsidersOnly 8.10% of the stock of Artivion is held by insiders.Percentage Held by Institutions86.37% of the stock of Artivion is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Artivion are expected to grow by 123.08% in the coming year, from $0.26 to $0.58 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Artivion is -27.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Artivion is -27.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArtivion has a P/B Ratio of 3.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Artivion Stock (NYSE:AORT)Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.Read More AORT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AORT Stock News HeadlinesApril 22, 2024 | prnewswire.comArtivion Announces Release Date and Teleconference Call Details for First Quarter 2024 Financial ResultsApril 19, 2024 | finance.yahoo.comArtivion's (NYSE:AORT) investors will be pleased with their notable 43% return over the last yearApril 24, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.April 1, 2024 | finance.yahoo.comArtivion to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceMarch 20, 2024 | investing.comArtivion's VP regulatory sells shares worth over $29kMarch 17, 2024 | uk.investing.comArtivion VP regulatory sells shares worth $79,880March 16, 2024 | uk.investing.comArtivion executive sells shares worth nearly $100kMarch 6, 2024 | prnewswire.comArtivion to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services ConferenceApril 24, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.February 21, 2024 | finance.yahoo.comWall Street Analysts Think Artivion (AORT) Could Surge 30.7%: Read This Before Placing a BetFebruary 16, 2024 | finance.yahoo.comArtivion, Inc. (NYSE:AORT) Q4 2023 Earnings Call TranscriptFebruary 15, 2024 | msn.comArtivion (AORT) Surpasses Q4 Earnings and Revenue EstimatesFebruary 15, 2024 | finance.yahoo.comArtivion Inc (AORT) Reports Solid Revenue Growth and Robust EBITDA Increase in Q4 and Full Year 2023February 15, 2024 | finance.yahoo.comArtivion Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 15, 2024 | prnewswire.comArtivion Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 14, 2024 | finance.yahoo.comAORT Apr 2024 12.500 putFebruary 14, 2024 | benzinga.comArtivion's Earnings: A PreviewFebruary 1, 2024 | finance.yahoo.comArtivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2023 Financial ResultsJanuary 29, 2024 | finance.yahoo.comArtivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 60th Society of Thoracic Surgery Annual MeetingJanuary 21, 2024 | morningstar.comArtivion Inc AORTJanuary 18, 2024 | finance.yahoo.comArtivion Obtains $350 Million in Senior Secured Credit FacilitiesJanuary 15, 2024 | finance.yahoo.comThere Are Reasons To Feel Uneasy About Artivion's (NYSE:AORT) Returns On CapitalDecember 18, 2023 | finance.yahoo.comArtivion, Inc. (NYSE:AORT) Soars 36% But It's A Story Of Risk Vs RewardDecember 11, 2023 | finance.yahoo.comArtivion, Inc. (NYSE:AORT) is a favorite amongst institutional investors who own 78%December 8, 2023 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Artivion (AORT)December 7, 2023 | msn.comArtivion appoints Lance A. Berry as EVP, CFO; reaffirms FY23 outlookDecember 6, 2023 | finance.yahoo.comArtivion Appoints Lance A. Berry as Executive Vice President, Chief Financial Officer; Announces Retirement of D. Ashley Lee, Chief Financial OfficerSee More Headlines Receive AORT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Artivion and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/15/2024Today4/24/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNYSE:AORT CUSIPN/A CIK784199 Webwww.cryolife.com Phone(770) 419-3355Fax770-426-0031Employees1,500Year FoundedN/APrice Target and Rating Average Stock Price Target$23.50 High Stock Price Target$25.00 Low Stock Price Target$22.00 Potential Upside/Downside+13.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.75) Trailing P/E RatioN/A Forward P/E Ratio79.92 P/E GrowthN/ANet Income$-30,690,000.00 Net Margins-8.67% Pretax Margin-6.10% Return on Equity3.02% Return on Assets1.09% Debt Debt-to-Equity Ratio1.10 Current Ratio4.85 Quick Ratio3.43 Sales & Book Value Annual Sales$354 million Price / Sales2.42 Cash Flow$0.80 per share Price / Cash Flow26.07 Book Value$6.87 per share Price / Book3.02Miscellaneous Outstanding Shares41,200,000Free Float37,863,000Market Cap$856.14 million OptionableOptionable Beta1.67 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. James Patrick Mackin (Age 57)Chairman, President & CEO Comp: $1.63MMs. Jean F. Holloway Esq. (Age 67)Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary Comp: $636.72kMr. John E. Davis (Age 59)Senior VP & Chief Commercial Officer Comp: $609.91kDr. Marshall S. Stanton M.D. (Age 67)Senior VP of Clinical Research & Chief Medical Officer Comp: $615.55kMs. Amy D. Horton CPA (Age 54)VP & Chief Accounting Officer Mr. Matthew A. Getz (Age 55)VP of Human Resources & Chief Human Resources Officer Dr. Robert C. Thomson (Age 54)Vice President of Research & Development Mr. Florian TyrsVice President of Global OperationsMore ExecutivesKey CompetitorsParagon 28NYSE:FNAMiMedx GroupNASDAQ:MDXGAtrionNASDAQ:ATRIOrthoPediatricsNASDAQ:KIDSTreace Medical ConceptsNASDAQ:TMCIView All CompetitorsInsiders & InstitutionsMesirow Financial Investment Management Inc.Sold 3,801 shares on 4/19/2024Ownership: 0.031%Wasatch Advisors LPBought 564,549 shares on 4/18/2024Ownership: 2.630%Allspring Global Investments Holdings LLCBought 4,154 shares on 4/18/2024Ownership: 0.014%Register Financial Advisors LLCBought 5,401 shares on 4/16/2024Ownership: 0.013%GAMMA Investing LLCBought 505 shares on 4/5/2024Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions AORT Stock Analysis - Frequently Asked Questions Should I buy or sell Artivion stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Artivion in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AORT shares. View AORT analyst ratings or view top-rated stocks. What is Artivion's stock price target for 2024? 2 Wall Street analysts have issued 12-month price targets for Artivion's shares. Their AORT share price targets range from $22.00 to $25.00. On average, they anticipate the company's share price to reach $23.50 in the next twelve months. This suggests a possible upside of 13.1% from the stock's current price. View analysts price targets for AORT or view top-rated stocks among Wall Street analysts. How have AORT shares performed in 2024? Artivion's stock was trading at $17.88 at the beginning of 2024. Since then, AORT stock has increased by 16.2% and is now trading at $20.78. View the best growth stocks for 2024 here. When is Artivion's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our AORT earnings forecast. How were Artivion's earnings last quarter? Artivion, Inc. (NYSE:AORT) posted its quarterly earnings data on Thursday, February, 15th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.24. The company earned $93.67 million during the quarter, compared to analysts' expectations of $89.75 million. Artivion had a negative net margin of 8.67% and a positive trailing twelve-month return on equity of 3.02%. What ETFs hold Artivion's stock? ETFs with the largest weight of Artivion (NYSE:AORT) stock in their portfolio include ROBO Global Healthcare Technology and Innovation ETF (HTEC), Invesco S&P SmallCap Health Care ETF (PSCH) and Unusual Whales Subversive Democratic Trading ETF (NANC).iShares U.S. Medical Devices ETF (IHI). What guidance has Artivion issued on next quarter's earnings? Artivion issued an update on its FY 2024 earnings guidance on Friday, February, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $382.0 million-$396.0 million, compared to the consensus revenue estimate of $384.3 million. Who are Artivion's major shareholders? Artivion's stock is owned by many different institutional and retail investors. Top institutional shareholders include Wasatch Advisors LP (2.63%), Mesirow Financial Investment Management Inc. (0.03%), Allspring Global Investments Holdings LLC (0.01%), Register Financial Advisors LLC (0.01%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Amy Horton, Andrew M Green, David Ashley Lee, Dennis B Maier, James P Mackin, Jean F Holloway, John E Davis, Marshall S Stanton, Matthew A Getz and Rochelle L Maney. View institutional ownership trends. How do I buy shares of Artivion? Shares of AORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:AORT) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyYour Money is Not SafeAmerican AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artivion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
